Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 8/20 | 0.47 |
| ▸ | IP6K1 | Q92551 | 3/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.36 |
| ▸ | PIM1 | P11309 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.36 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15928076 | 0.94 | PARP1 (0.48) | PARP1IP6K1CHEK1PIM1ALDH1A1 | |
| SCHEMBL642058 | 0.85 | PARP1 (0.47) | PARP1IP6K1CHEK1PIM1ALDH1A1 | |
| SCHEMBL24168199 | 0.85 | PARP1 (0.44) | PARP1IP6K1CHEK1PIM1RPS6KA3 | |
| SCHEMBL300019 | 0.84 | PARP1 (0.46) | PARP1IP6K1CHEK1PIM1ALDH1A1 | |
| SCHEMBL24168319 | 0.84 | PARP1 (0.50) | PARP1IP6K1CHEK1PIM1ALDH1A1 | |
| SCHEMBL24167307 | 0.83 | KDM4E (0.46) | PARP1IP6K1CHEK1PIM1ALDH1A1 | |
| SCHEMBL24167407 | 0.82 | IP6K1 (0.43) | PARP1IP6K1 | |
| SCHEMBL157879 | 0.81 | PARP1 (0.52) | PARP1IP6K1CHEK1PIM1ALDH1A1 | |
| SCHEMBL29365309 | 0.81 | PARP1 (0.52) | PARP1IP6K1CHEK1PIM1ALDH1A1 | |
| SCHEMBL24167710 | 0.81 | ALDH1A1 (0.47) | PARP1IP6K1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014117698-A1 | TRICYCLIC DERIVATIVE CONTAINING QUINAZOLINE STRUCTURE, PREPARATION METHOD AND USE THEREOF | 江苏奥赛康药业股份有限公司 (CN) | 2014-08-07 | — | — | WO | disclosed |
| US-8367824-B2 | Reacting anthranilic acid with formic acid compound in presence of a catalyst and solvent | UBE INDUSTRIES LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| EP-1477481-B1 | PROCESS FOR PRODUCING QUINAZOLIN-4-ONE DERIVATIVE | UBE INDUSTRIES (JP) | 2009-07-22 | — | — | EP | disclosed |
| US-20050080262-A1 | Process for producing quinazolin-4-one derivative | UBE INDUSTRIES, LTD. (JP) | 2005-04-14 | — | — | US | disclosed |
| EP-1477481-A1 | PROCESS FOR PRODUCING QUINAZOLIN-4-ONE DERIVATIVE | Ube Industries, Ltd. (JP) | 2004-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080262-A1 | Process for producing quinazolin-4-one derivative | NQO2, SDHA, CYP3A4 | PARP1 712/4885IP6K1 2906/4885PRSS1 1196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.